Our study extends this paradigm by incorporating accessible biomarkers of CVD into a model that already includes baseline demographics (age, sex), cognitive screening (MoCA), genetic information (APOE genotyping), along with clinically accessible neuroimaging measures of brain atrophy (MTL volume). The gene discussed is APOE; the disease is Brain atrophy.